Biohaven Prices of $230 Million Public Offering of Common Shares

Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.  In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public offering price, less underwriting discounts, and commissions.  The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven.  The offering is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.

J.P. Morgan, Morgan Stanley, TD Cowen, and Piper Sandler & Co. are acting as the joint lead book-running managers of the offering. Cantor is acting as a book-runner of the offering.  Baird is also acting as a book-runner of the offering.